Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT05554393
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 335
- Registration Number
- NCT05554406
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05520567
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT05476770
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05471700
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guandong, China
Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Joshua Zeidner
- Target Recruit Count
- 53
- Registration Number
- NCT05442216
- Locations
- 🇺🇸
Lifespan Health System Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 20
- Registration Number
- NCT05433532
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 181
- Registration Number
- NCT05428969
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇫🇮Tampere University Hospital, Tampere, Finland
🇺🇸City of Hope National Medical Center, Duarte, California, United States
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 124
- Registration Number
- NCT05404906
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Alice Mims
- Target Recruit Count
- 125
- Registration Number
- NCT05401097
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.